🚀 **Exciting News in Mental Health Treatments!** 🚀 At Serenity Mental Health Centers, we are committed to providing cutting-edge, effective treatments for mental health. Recent research highlights the potential of ketamine as a powerful tool for those struggling with treatment-resistant depression. 🔹 **Groundbreaking Study Results**: A recent study by Massachusetts General Brigham has shown that intravenous (IV) ketamine is almost as effective as electroconvulsive therapy (ECT) in treating severe depression, but with significantly fewer side effects. This study involved 403 patients and demonstrated a 55% improvement in depressive symptoms among those treated with ketamine. [Harvard Gazette](https://lnkd.in/gFG83gSa) 🔹 **Personalized Treatment Potential**: Yale University researchers found that ketamine produces varied responses in the brain, linked to individual gene expression patterns. This finding could pave the way for personalized treatment plans, enhancing ketamine’s effectiveness. [Yale News](https://lnkd.in/gF_hPVQV) 🔹 **Clinical Success**: The Bio-K study, which involved major institutions like the University of Michigan and Johns Hopkins University, reported that over 50% of patients achieved remission after three ketamine infusions. This study underscores ketamine's rapid and potent effects in alleviating depressive symptoms. [Neuroscience News](https://lnkd.in/gjbpcsXU) At Serenity Mental Health Centers, we are dedicated to bringing these innovative treatments to our patients. If you or a loved one is battling depression and conventional treatments haven’t helped, ketamine therapy might be the breakthrough you need. 💬 **Join the conversation and learn more about how we're transforming mental health care with advanced therapies!** #MentalHealth #KetamineTherapy #DepressionTreatment #InnovativeCare #SerenityMentalHealth
Serenity Healthcare’s Post
More Relevant Posts
-
Interesting! Are you feeling anxious? Your gut might be the reason. Yet another finding that adds to the key importance of gut microbiota in regulating mood and behaviour. If you're on a path to improve your mental health, reach out to me and provide insights on what are the key attributes you would like to have in your digital mental health service (DMHS).
Gut microbes may play role in social anxiety disorder A study published in PNAS suggests that gut microbes may play a role in social anxiety disorder (SAD). Researchers found that the gut microbiome, the collection of bacteria and other organisms in the gastrointestinal system, differs in people with SAD compared to healthy individuals. This finding is part of a growing body of research showing that gut microbes can influence the brain. In the study, researchers transplanted microbes from the guts of people with SAD into mice. These mice then exhibited an increased response to social fear. This builds on previous research showing similar results for conditions like depression and irritable bowel syndrome. Professor John Cryan, a co-author of the research, emphasised the importance of gut flora in disorders like SAD. He suggested that looking after our gut microbes throughout development and adulthood is crucial for maintaining a properly functioning social brain. The study involved taking faecal samples from six healthy people and six people with SAD. Metagenomic analysis confirmed significant differences in the gut microbiome between the two groups. The samples were then transferred into laboratory mice, which had been treated with antibiotics to remove their natural gut microbes. The mice's responses to various stimuli were subsequently observed. This research highlights the potential role of the gut microbiome in mental health and opens up new possibilities for therapies targeting gut microbes. Full Study: https://lnkd.in/gBU4JZhd #microbiome #gutbrainconnection #mentalhealth
To view or add a comment, sign in
-
Gut microbes may play role in social anxiety disorder A study published in PNAS suggests that gut microbes may play a role in social anxiety disorder (SAD). Researchers found that the gut microbiome, the collection of bacteria and other organisms in the gastrointestinal system, differs in people with SAD compared to healthy individuals. This finding is part of a growing body of research showing that gut microbes can influence the brain. In the study, researchers transplanted microbes from the guts of people with SAD into mice. These mice then exhibited an increased response to social fear. This builds on previous research showing similar results for conditions like depression and irritable bowel syndrome. Professor John Cryan, a co-author of the research, emphasised the importance of gut flora in disorders like SAD. He suggested that looking after our gut microbes throughout development and adulthood is crucial for maintaining a properly functioning social brain. The study involved taking faecal samples from six healthy people and six people with SAD. Metagenomic analysis confirmed significant differences in the gut microbiome between the two groups. The samples were then transferred into laboratory mice, which had been treated with antibiotics to remove their natural gut microbes. The mice's responses to various stimuli were subsequently observed. This research highlights the potential role of the gut microbiome in mental health and opens up new possibilities for therapies targeting gut microbes. Full Study: https://lnkd.in/gBU4JZhd #microbiome #gutbrainconnection #mentalhealth
To view or add a comment, sign in
-
POST COVID DEPRESSION & ANXIETY: Long COVID causes inflammation in the brain that can cause the release of cytokines (proteins that are secreted from certain cells in the immune system) that are known to cause fatigue, low energy, and low motivation ― symptoms which are also associated with depression and anxiety. What's more, if a patient had a serious case of acute COVID which led them to go on a ventilator, that too can cause changes in the brain. This means they could have had problems with their oxygenation status, and oxygen deprivation can have both acute and long-term effects on the brain. People can become delirious, meaning they have disturbances in their cognitive function, like attention and awareness (deficits). The study, published in The Lancet, followed 236,379 patients with long COVID. The investigators found that 62% of patients had received either a neurologic or a psychological diagnosis 6 months after being diagnosed with acute COVID. nsomnia itself can be a symptom of depression. It may also be a physical symptom of long COVID similar to pain or difficulty breathing. And if you're not sleeping well, you're going to feel worse both physically and mentally. We also know that pain can affect mood and mood can affect pain — it's a bio-directional relationship. For example, if you're in pain, you're going to feel bad, and if you're depressed, that can also make your pain experience worse. Additionally, if you're in pain, it causes a physical limitation that can keep you from work or seeing your friends and family. These can all impact your social life. Limitations at work can also cause financial stress, which has been shown to impact mental health. https://lnkd.in/eKu9e2Hx NEED SUPPORT? Promedview coaches and advocates can help you navigate your recovery. Learn more at https://lnkd.in/dXBhFW8v #postcoviddepression #DepressionAndAnxietyAwareness #longcovidawareness #LongCOVIDkids #neurocovid
To view or add a comment, sign in
-
Digital Health | Evidence Generation | Research Strategy | People Leader | Science Communicator | Behavioral Science | Recovered Academic
Since I learned about the Beck Depression Inventory in grad school, I've often thought about the potential for different subtypes of depression - at least in terms of psychological vs. somatic symptoms. Well, an interesting new paper from researchers at Verily (including the amazing Jordan Tharp, PhD), Stanford and Duke outlines three studies they conducted examining the underlying factor structure of the PHQ-9 - and they propose evidence for four depressive symptom subtypes on the PHQ-9: 1. An affective subtype (people reporting anedhonia and depressed mood) 2. A somatic subtype (people reporting problems with sleep, fatigue, and appetite) 3. An internalizing subtype (people reporting guilt/shame and suicidality) 4. A sensorimotor subtype (people reporting problems with concentration and psychomotor symptoms) This work will need to be replicated with more diverse samples (especially international samples) and with other measures of depression (particularly given the PHQ-9 is much briefer than some other measures of depression, limiting the number of symptoms assessed) - but I think it's important that those of us in digital health start thinking about different symptom profiles, when the mental health arena still tends to think of depression as a unipolar construct. For example - is our intervention suitable for all symptom profiles? Depending on your intervention activities, you may be targeting a specific type of symptom while having little effect on others. Understanding this can help you identify what users may benefit minimally from your intervention, or even be at risk for dropout. Understanding someone's symptom profile can also help us tailor interventions to their needs by identifying what activities will be most effective for them. Someone presenting with an affective subtype may need a different program than someone with a sensorimotor type. We know it's not a one-size fits all solution, and this approach may help us unlock a way to personalize more effectively. I know my brain is already thinking about the various ways to apply this in research and in practice! #research #mentalhealth #digitaltherapeutics
Identifying a stable and generalizable factor structure of major depressive disorder across three large longitudinal cohorts
sciencedirect.com
To view or add a comment, sign in
-
📃Scientific paper: Chronic kidney disease and severe mental illness: a scoping review Abstract: Background People who have severe mental illness experience higher rates of long-term conditions and die on average 15–20 years earlier than people who do not have severe mental illness, a phenomenon known as the mortality gap. Long-term conditions, such as diabetes, impact health outcomes for people who have severe mental illness, however there is limited recognition of the relationship between chronic kidney disease and severe mental illness. Therefore, the aim of this scoping review was to explore the available evidence on the relationship between chronic kidney disease and severe mental illness. Methods Electronic databases, including MEDLINE, Embase, CINAHL, and PsycINFO were searched. The database searches were limited to articles published between January 2000–January 2022, due to significant progress that has been made in the detection, diagnosis and treatment of both SMI and CKD. Articles were eligible for inclusion if they explored the relationship between SMI and CKD (Stages 1–5) in terms of prevalence, risk factors, clinical outcomes, and access to treatment and services. Severe mental illness was defined as conditions that can present with psychosis, including schizophrenia, schizoaffective disorder, bipolar disorder, and other psychotic disorders. Thirty articles were included in the review. Results The included studies illustrated that there is an increased risk of chronic kidney disease amongst people who have severe mental illness, compared to those... Continued on ES/IODE ➡️ https://etcse.fr/R7ZpN ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
Chronic kidney disease and severe mental illness: a scoping review
ethicseido.com
To view or add a comment, sign in
-
📃Scientific paper: Chronic kidney disease and severe mental illness: a scoping review Abstract: Background People who have severe mental illness experience higher rates of long-term conditions and die on average 15–20 years earlier than people who do not have severe mental illness, a phenomenon known as the mortality gap. Long-term conditions, such as diabetes, impact health outcomes for people who have severe mental illness, however there is limited recognition of the relationship between chronic kidney disease and severe mental illness. Therefore, the aim of this scoping review was to explore the available evidence on the relationship between chronic kidney disease and severe mental illness. Methods Electronic databases, including MEDLINE, Embase, CINAHL, and PsycINFO were searched. The database searches were limited to articles published between January 2000–January 2022, due to significant progress that has been made in the detection, diagnosis and treatment of both SMI and CKD. Articles were eligible for inclusion if they explored the relationship between SMI and CKD (Stages 1–5) in terms of prevalence, risk factors, clinical outcomes, and access to treatment and services. Severe mental illness was defined as conditions that can present with psychosis, including schizophrenia, schizoaffective disorder, bipolar disorder, and other psychotic disorders. Thirty articles were included in the review. Results The included studies illustrated that there is an increased risk of chronic kidney disease amongst people who have severe mental illness, compared to those... Continued on ES/IODE ➡️ https://etcse.fr/R7ZpN ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
Chronic kidney disease and severe mental illness: a scoping review
ethicseido.com
To view or add a comment, sign in
-
Case Study: Burden of Illness - Mental Health Disorders in MS Patients OM1, Inc. conducted a study on the burden of mental health conditions in patients with Multiple Sclerosis. With the help of our PremiOM MS Real-World Dataset, we were able to: ✔ Identify the population of MS patients with comorbid mental health conditions and ✔ Understand unmet mental health intervention and psychotherapy needs and impact on disease activity. The Solutioning we used: ✔ We examined patients with MS and mental health diagnosis, medication or treatment. ✔ Identified patient and disease characteristics associated with depression and anxiety related to comorbidities. Our Findings were: ✔ Study conducted on roughly 19,000 MS patients ✔ About 80% of MS patients had a comorbid mental health condition ✔ Anxiety, depression, and substance abuse disorders were the most frequent. What’s the value? ✔ The nuances of comorbidities and how they influence the primary disease of interest are often misunderstood or overlooked. ✔ Helps provide explainability around patient journeys Interested in learning more about our Multiple Sclerosis PremiOM dataset and see how OM1 can assist in your current research studies? Check out the following links; 📍 Book a meeting with us: https://lnkd.in/eJcKBAJK 📍 MS eBook: https://lnkd.in/e2GR4xB8 📍 MS Smart Link : https://lnkd.in/efr9VREX #ms #neurology #rwd #patientjourneys
To view or add a comment, sign in
-
"After administering more than 23,000 ketamine treatments over the past 5 years, we obviously believe in the drug’s importance—saving and changing lives of many patients who suffer from intractable mental health disease. But ketamine is no panacea for treatment-resistant depression (TRD) and other debilitating mental health conditions. Other solutions exist that are helping to make treatment-resistant conditions more treatable than ever before. And while the explosion of ketamine-for-cash clinics did a lot to build awareness of ketamine, it also provided a myopic, wonder-drug view that overlooks alternatives." - Brian Johns, MD, MFA Read Dr. Johns's complete insights in his article published on Psychology Today! #brainhealth #mentalhealth #news
Tackling Treatment Resistant Depression with Multiple Tools
psychologytoday.com
To view or add a comment, sign in
-
🍄 PsychedelicInsights.com | The psychological guidance of private psychedelic experiences | Public Speaker | Psychedelic Advocate | Royal Marine Corps veteran | Opti-Mystic | Multi Dimensional Philosopher | Hope dealer
#Spiritual #psychedelic #psilocybin experiences can have #therapeutic #sideeffects. Research on psilocybin is extensive, covering a wide range of psychological and neurological conditions. Here's a list of afflictions and diseases currently being explored in studies involving psilocybin: Obsessive-Compulsive Disorder (#OCD): Psilocybin has shown potential in reducing symptoms of OCD in clinical settings (Carhart-Harris et al., 2016). Treatment-Resistant #Depression: Various studies have highlighted the efficacy of psilocybin in alleviating symptoms of major depressive disorders that are resistant to conventional treatments (Daniel & Haberman, 2017). Post-Traumatic Stress Disorder (#PTSD): Psilocybin is being investigated for its therapeutic potential in treating PTSD, with some promising results in clinical trials (Ross et al., 2016). #Anxiety Disorders: There's growing evidence supporting the use of psilocybin in treating various forms of anxiety, particularly in the context of life-threatening diseases (Osorio Vargas et al., 2020). #Alcohol and #Tobacco #Addiction: Studies have shown that psilocybin may help reduce dependency on substances like alcohol and tobacco (Johnson & Griffiths, 2017). #Anorexia Nervosa: There is ongoing research into psilocybin's effects on eating disorders, including anorexia, although this area is less developed. #Bipolar Disorder: Currently, there is limited direct research on psilocybin's effects on bipolar disorder, though its impact on related mood disorders is under study. End-of-Life Psychological #Distress: Psilocybin has been explored for its potential to alleviate anxiety and depression in patients facing terminal illnesses, helping to improve their quality of life (Griffiths et al., 2017). Cluster #Headaches: There is anecdotal evidence and some clinical interest in psilocybin's ability to treat cluster headaches, though more rigorous scientific research is needed. These studies indicate a broad and expanding interest in the therapeutic potential of psilocybin across a variety of conditions, highlighting its significance in contemporary psychopharmacology. For your own spiritual psilocybin truffle experience, please learn more about our services at psychedelicinsights.com
To view or add a comment, sign in
-
Promising research by Kaeleigh Fearn and Kallol Kumar Bhattacharyya shows that psychedelic therapy may boost cognitive health in older adults. Data from the MIDUS study revealed a 10.2% improvement in executive function and a significant reduction in depressive symptoms in those aged 42 to 92. These findings highlight the potential of psychedelics for enhancing mental wellness. #CognitiveHealth #MentalWellness #Psychedelics #Psylocibin https://lnkd.in/gdWnzgYe
Is Use of Psychedelic Drugs a Risk or Protective Factor for Late-Life Cognitive Decline? - Kaeleigh Fearn, Kallol Kumar Bhattacharyya, 2024
journals.sagepub.com
To view or add a comment, sign in
15,456 followers